Tag:
AbbVie
Latest Headlines
Latest Headlines
AbbVie, Galapagos extend JAK1 pact into Crohn's disease with $50M carrot
The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.
Mined doctor-patient data gives drugmakers insight for targeted marketing
The recent layoffs of hundreds of drug sales reps mean there are fewer people in the field calling on doctors to see what they are prescribing. But they don't have to--drugmakers have found new tools that actually can tell them more about doctors' prescribing patterns than the physicians even know themselves.
AbbVie grabs rights to biotech startup's anti-gluten drug for $70M upfront
The pharma giant has secured rights to an experimental therapy for celiac disease from Alvine Pharmaceuticals for $70 million in upfront payments and the promise of more money down the road.
AbbVie research chief heads for the exits, amid rash of top R&D departures
AbbVie filed forms with the SEC on Friday saying that John Leonard, the company's senior vice president and CSO, will be leaving in the coming months.
AbbVie's senior R&D exec Leonard joins exodus from the top ranks
The epidemic of retirements among top R&D executives is continuing with the news that AbbVie's senior researcher is headed for the exits. AbbVie filed forms with the SEC on Friday saying that John Leonard, the company's senior vice president and CSO will be leaving in the coming months. And the company says that one of his last acts will be advising the company on his successor.
AbbVie, Pfizer's Zoetis deals ignite enormous leap in M&A value
Pfizer's spinoff of its animal health business into Zoetis is the biggest IPO this year. And the spinoff that created the newest Big Pharma company, AbbVie, was no slouch.
The pharma spin-offs have just begun
After all, investors and shareholders responded strongly to Pfizer's animal-health spinoff and nutrition-unit sale--so much so that analysts are calling on CEO Ian Read for more.
The pharma spinoffs have just begun, bankers figure
Want to see more divestment action in Big Pharma? Just wait. That's what investment bankers are predicting, now that Pfizer and AbbVie have led the way.
EMA vows to battle AbbVie in courts for full data transparency
AbbVie and InterMune may have won at least a temporary reprieve in their fight to stop the EMA from releasing trial data on their drugs.
Humira carries AbbVie in its first quarter as standalone company
AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and allowed Abbvie to report better than expected earnings in its first earnings report as a stand-alone company.
